Akèy › Limfòm Burkitt › Texas

Etid klinik pou Limfòm Burkitt nan Texas

24 etid pou Limfòm Burkitt ap chèche patisipan nan sit nan Texas.

Vil nan Texas

Tèks ofisyèl etid la (Anglè)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Dell Children's Medical Center of Central Texas, Austin
Driscoll Children's Hospital, Corpus Christi
Medical City Dallas Hospital, Dallas
ak 10 plis

Ap rekriteFaz 2

366 Days – 46 Years · Tout sèks · Mizajou Sep 28, 2026 · NCT06124157

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Dell Children's Medical Center of Central Texas, Austin
Driscoll Children's Hospital, Corpus Christi
Medical City Dallas Hospital, Dallas
ak 7 plis

Ap rekriteFaz 2

365 Days · Tout sèks · Mizajou Sep 25, 2026 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

The University of Texas MD Anderson Cancer Center, Houston

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07648264

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

University of Texas MD Anderson Cancer Center ( Site 1007), Houston

Ap rekriteFaz 1/2

6 Months – 25 Years · Tout sèks · Mizajou Sep 17, 2026 · NCT06395103

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

Baylor College Medical Center (Data Collection Only), Houston
Texas Children's Hospital (Data Collection), Houston

Ap rekriteFaz 3

Laj 1 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07223021

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Methodist Children's Hospital, San Antonio

Ap rekriteFaz 1

Laj 0 a 18 · Tout sèks · Mizajou Sep 16, 2026 · NCT06173518

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Baylor University Medical Center, Dallas

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT03666000

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Houston Methodist Hospital, Houston

Ap rekriteFaz 3

Laj 18 a 39 · Tout sèks · Mizajou Sep 2, 2026 · NCT03150693

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Dell Children's Medical Center of Central Texas, Austin
Driscoll Children's Hospital, Corpus Christi
Medical City Dallas Hospital, Dallas
ak 10 plis

Ap rekriteFaz 2

Laj 1 a 30 · Tout sèks · Mizajou Sep 1, 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Dell Children's Medical Center of Central Texas, Austin
Driscoll Children's Hospital, Corpus Christi
Medical City Dallas Hospital, Dallas
ak 12 plis

Ap rekriteFaz 3

365 Days – 25 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03959085

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Research Site, Houston

Ap rekriteFaz 1/2

Laj 12 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT06137118

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

University of Texas, Southwestern, Dallas
Baylor Texas Children's Hospital, Houston

Ap rekriteFaz 2

Laj 7 a 25 · Tout sèks · Mizajou Aug 19, 2026 · NCT05082519

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

MD Anderson Cancer Center, Houston

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT06287229

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

M D Anderson Cancer Center, Houston

Ap rekriteFaz 2

Laj 15 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT03136146

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

University of Texas MD Anderson Cancer Center, Houston

Ap rekriteFaz 1/2

Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

M D Anderson Cancer Center, Houston

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Jul 15, 2026 · NCT01371630

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

Research Site, Houston

Ap rekriteFaz 1/2

Laj 12 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT07109219

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Texas Children's Hospital, Houston

Ap rekriteEtid obsèvasyon

Laj 0 a 38 · Tout sèks · Mizajou Jun 4, 2026 · NCT06131801

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

M D Anderson Cancer Center, Houston

Ap rekriteFaz 2

Laj 14 ak plis · Tout sèks · Mizajou May 20, 2026 · NCT02877303

Study of SGR-1505 in Mature B-Cell Neoplasms

University of Texas Southwestern, Dallas

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT05544019

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

University of Texas MD Anderson Cancer Center, Houston

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Nov 5, 2025 · NCT04260022

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Sarah Cannon - St. David's South Austin Medical Center, Austin
MD Anderson Cancer Center, Houston
Sarah Cannon - Texas Transplant Institute at Methodist Hospital, San Antonio

Ap rekriteFaz 1/2

Laj 15 a 50 · Tout sèks · Mizajou Sep 9, 2025 · NCT04150497

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

The University of Texas M. D. Anderson Cancer Center, Houston
Methodist Healthcare System, San Antonio

Ap rekriteFaz 2

Laj 1 a 25 · Tout sèks · Mizajou May 4, 2025 · NCT03509961

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

MD Anderson Cancer Center, Houston

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Nov 15, 2024 · NCT06034275

Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.